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Key Points 22 
Whilst post-prandial hypotension is not uncommon in older people and is of clinical 23 
significance, there are only a few studies which have focused on the pharmacological 24 
management of symptomatic patients. 25 
Although drugs can attenuate the post-meal fall in BP, evidence is lacking with regard to 26 
their effect on those with symptomatic post-prandial hypotension. 27 
These studies highlight the need of rigorous clinical trials in the treatment of this clinically 28 
important condition. 29 
  30 
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Abstract 31 
Background: A fall in blood pressure (BP) after meals (postprandial hypotension [PPH]), is 32 
common in older adults and associated with significant morbidity and mortality.  33 
Objectives: Our aim was to systematically review the current literature on the 34 
pharmacological treatment of post-meal reductions in BP.  35 
Design: A systematic literature search and standardised data collection of randomised 36 
controlled studies on the pharmacological prevention of postprandial falls in BP in adults 37 
using MEDLINE (1950-), EMBASE (1980-) and CINAHL  databases was conducted up to July 38 
2013. Hand-searching of bibliographies of relevant reports was also carried out to identify 39 
all potentially eligible studies.  40 
Setting: Systematic Review of RCTs using PRISMA guidelines 41 
Measurements: Papers were assessed using CASP (Critical Appraisal Skills Programme) for 42 
randomised controlled trials. 43 
Results: Thirteen papers reporting twelve studies (one study was reported in two papers) 44 
demonstrated that caffeine (five studies), acarbose, 3, 4-DL-threodihydroxyphenylserine 45 
(DL-DOPS), guar gum (three studies) and octreotide (two studies) statistically attenuated the 46 
postprandial BP fall. One caffeine study did not show this. However most studies did not 47 
include patients with symptomatic PPH and therefore interpretation and application of 48 
these findings to this patient group should be made with caution. For symptomatic 49 
participants there was improvement with acarbose but none with caffeine.  Differences in 50 
the way the data were presented in the studies did not allow for quantification of treatment 51 
effects by meta-analysis. 52 
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Conclusion: Drug interventions can attenuate postprandial BP falls, but they may not 53 
necessarily be effective in people with symptomatic PPH.  54 
  55 
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Background 56 
Postprandial hypotension (PPH) can be defined as a reduction in the systolic BP (SBP) of 57 
≥20mmHg within 2 hours of the start of a meal or if SBP falls to ≤90mmHg within this period 58 
where the pre-prandial SBP was ≥100mmHg. [1] Post-prandial falls in BP are much more 59 
common in older people, with prevalence rates up to 36% of those residing in care homes 60 
[2,3] and as high as 67% in the older hospital population [4].  61 
 62 
Symptomatic PPH can result in dizziness, falls, confusion, visual disturbances, nausea, 63 
tiredness and syncope as well as resulting in a poor quality of life. [1,4,5] While PPH may not 64 
always be associated with symptoms, the clinical impact can be substantial; being present in 65 
half of those with “unexplained” syncope [1], as well as being associated with an increased 66 
incidence of acute vascular events such as stroke or angina and increased mortality.[2]  67 
 68 
The largest post-prandial reductions in BP are seen in those aged over 65 years and usually 69 
occur within 60-120 minutes of ingestion of an energy source (whether liquid or solid). This 70 
is particularly the case where there is a high simple carbohydrate substrate content e.g. 71 
glucose (but not with fructose). [6, 7, 8] Furthermore the post-prandial fall in BP is 72 
independent of the presence or absence of systemic hypertension [6, 7, 8] even when anti-73 
hypertensive medication is withdrawn. [9] This post-prandial BP decrease reflects the failure 74 
of the normal homeostatic mechanisms to maintain BP levels in the face of a fall in systemic 75 
vascular resistance due to splanchnic and peripheral vasodilation not being compensated 76 
for by an increase in cardiac output. [1, 10]  77 
Page 5 of 52 
 
Drug Treatment of Post-Prandial Falls in BP 
  14/11/13 
 
 78 
Evidence suggests caffeine (an adenosine antagonist which blocks splanchnic 79 
methlyxanthine sensitive adenosine receptors) when given after meals can reduce post-80 
prandial symptoms and BP reduction [10, 11, 12] indicating adenosine may have an 81 
underlying pathophysiological role for inducing this splanchnic vasodilatation. Other studies 82 
have shown that in addition there is an impairment of cardiac baroreflex sensitivity in older 83 
people resulting in impaired heart rate (HR) and stroke volume responses leading to the 84 
failure to increase cardiac output to compensate for the fall in systemic vascular 85 
resistance.[9]  86 
 87 
In addition to some lifestyle measures [1], several other agents have also been tried in the 88 
treatment of PPH by addressing possible underlying pathophysiological mechanisms. For 89 
example acarbose, reduces complex carbohydrate breakdown thereby delaying gut glucose 90 
absorption [13, 14]. Whereas 3,4-DL-threodihydroxyphenylserine  DL-DOPS, is a 91 
norepinephrine precursor converts to norepinephrine in the peripheral and central nervous 92 
system to replace levels of norepinephrine in autonomic failure [15]. Guar gum reduces 93 
postprandial falls in BP by delaying gastric emptying and glucose absorption in the small 94 
intestine [16]. Other agents such as octreotide (which inhibits the vasodilation of the 95 
splanchnic vasculature by inhibiting vasoactive peptides) given before a meal has been also 96 
been shown to have some benefit in preventing PPH in older adults with hypertension [17], 97 
as has midodrine (an α1-adrenergic agonist) administered concomitantly with denopamine 98 
(a selective β1-adrenergic agonist). [18] 99 
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 100 
However although there is some evidence of positive effects these various agents being 101 
useful in this setting, the magnitude of the effects of these therapeutic agents in a 102 
randomised controlled trial setting has not been examined systematically. Here we report a 103 
systematic review of randomised controlled studies involving the pharmacological 104 
management of post-prandial hypotension and post-prandial falls in BP, using PRISMA 105 
guidelines [19].  106 
 107 
Methods 108 
Eligibility criteria 109 
Studies which specifically investigated the effect of the drug intervention on post-prandial 110 
change in BP were selected. They had to be controlled, randomised, studies which reported 111 
either supine and/or erect BP, and include administration of a standardised meal or glucose 112 
(oral/intraduodenal). Due to the nature of some treatments both open and blinded studies 113 
were included.  Both patients and normal volunteers were included in the analysis if they 114 
were over 18 years of age as long as the aim of the study was to assess the effects of 115 
treatment on postprandial BP changes.  116 
 117 
Information sources 118 
A search of MEDLINE (1950-), EMBASE (1980-) and CINAHL (1937-) was carried out on the 119 
16th of July 2013, limited to the English language and human subjects, and was followed by 120 
hand-searching of the bibliography of the full-text articles to identify potentially relevant 121 
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studies. Titles were screened by ACLO, whilst abstracts and papers were independently 122 
screened by ACLO and JFP, and discrepancies resolved by PKM. 123 
Search terms 124 
Search terms included “post-prandial hypotension.mp.” or “hypotension.mp.” or 125 
“Hypotension/or Hypotension, Orthostatic/” and “eating/ or meals.mp.” or “Food/ or 126 
prandial.mp. or Postprandial Period/”.  Individual drugs were searched including 127 
“octreotide.mp. or Octreotide/”, caffeine.mp. or Caffeine/”, “NSAIDS.mp. or Anti-128 
Inflammatory Agents, Non-Steroidal/”, “indomethacin.mp. or Indomethacin/”, 129 
“fludrocortisone.mp. or Fludrocortisone/”, “midodrine.mp. or Midodrine/”, “acarbose.mp. 130 
or Acarbose/”, “somatostatin.mp. or Somatostatin/”, in addition to more generic terms 131 
including “drug treatment.mp. or Adult/”, “drug therapy.mp. or Drug Therapy/”, Autonomic 132 
Nervous System Diseases/co, et, pp, th [Complications, Etiology, Physiopathology, Therapy]” 133 
Data collection 134 
Papers were assessed using the CASP (Critical Appraisal Skills Programme) approach for 135 
randomised controlled trials and are shown in the supplementary information, Table A. 136 
(Accessed 7th September 2012, http://www.casp-uk.net/find-appraise-act/). Data 137 
parameters were originally extracted by ACLO using a standardised form to assess paper 138 
suitability for meta-analysis. The form was developed specifically for the review after 139 
piloting with three randomly selected papers in the first instance to ensure all relevant data 140 
were captured.  ACLO and JFP independently reviewed papers for systematic review, and 141 
discrepancies resolved by PKM. 142 
Data items 143 
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Information on study participant characteristics (age, sex, and diagnosis), trial 144 
inclusion/exclusion criteria and drug intervention including dose and duration of treatment 145 
were extracted. The outcome measures of systolic and diastolic blood pressure or mean 146 
arterial pressure at baseline and with treatment for all arms of the study had to be available 147 
either as individual components of BP, MAP or as a change in these parameters. Results are 148 
given as mean ±SD mmHg unless otherwise stated. 149 
 150 
Risk of bias in individual studies 151 
Risk of bias for studies included was assessed including adequacy of sequence generation 152 
(presence of random component and method), allocation concealment (i.e. pre-153 
assignment), whether missing data was accounted for and if there was evidence of within 154 
study selective reporting or other bias.  155 
 156 
Summary measures 157 
Due to the inconsistencies in outcome measurements and reporting, it was not possible to 158 
synthesise summary statistics using a formal meta-analysis approach. 159 
 160 
Results 161 
Fourteen randomised studies were included in the final selection for systematic review 162 
(Figure 1).  The characteristics of the studies (including population and meal type) are shown 163 
in Table 1. Overall the studies were of good quality and the risks of bias within these studies 164 
are shown in Table 2. The timing of the intervention depended on the nature of the agent 165 
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being studied; in the majority of the studies the drug treatment was given before or with 166 
the meal or glucose load; and in the remainder it was immediately after the meal or glucose 167 
load. BP in all but two studies [10, 11] was not explicitly measured on more than one 168 
occasion at each time point. The majority of studies used an automated oscillometric BP 169 
monitor, others used an arteriosonde [20] or a Hawksley sphygmomanometer [10,11]. Only 170 
two studies [13, 22] were carried out in participants with a formal diagnosis of PPH using the 171 
defined criteria [1]. The hemodynamic responses but not the symptomatic relief of PPH 172 
were reported by the trials. Shorter-term studies were those which investigated the effects 173 
of a single dose of treatment within a 24 hour period. Longer-term studies include those 174 
where the intervention was continued for more than a 24 hour period. 175 
 176 
Shorter-term studies 177 
Caffeine 178 
There were six randomised controlled studies [10,11,20,22-24] involving caffeine 179 
administered in various doses and forms: as tea or coffee or as pure caffeine  in capsule 180 
form  (e.g. 60mg five times a day, 250mg capsule single intervention), four of these studies 181 
were double-blind [10,11,20,22]. Only one study by Lipsitz et al enrolled participants with 182 
confirmed PPH (defined as a fall in the supine or seated systolic BP (SBP) of at least 20mmHg 183 
within 60 minutes of the meal), with symptoms of weakness or dizziness. [22] Most 184 
participants in these trials were regular caffeine consumers and no adverse effects were 185 
reported with caffeine consumption.  186 
Onrot and colleagues [23] demonstrated in six participants with primary or secondary 187 
autonomic failure who were regular caffeine consumers but who had no history of PPH, that 188 
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a single 250mg dose of caffeine before a standardised meal (see Table 1) resulted in a 189 
significantly smaller post-prandial fall in SBP and DBP by 60 minutes (p<0.05) than without 190 
caffeine . As seen previously there was no significant difference in HR changes between 191 
placebo and caffeine phases in the studies. As no participants had a history of PPH, 192 
symptomatic differences with treatment were not recorded. 193 
Lenders et al [20] studying fifteen healthy participants who regularly consumed caffeine, 194 
showed no fall in  mean arterial pressure (MAP) from baseline after a single 250mg dose of 195 
caffeine given one hour before a standardised meal, compared to placebo, HR was also 196 
unchanged compared to baseline between placebo and caffeine phases.  197 
Heseltine and colleagues [10] showed a significant reduction in post-prandial standing and 198 
supine SBP fall with caffeine (200mg coffee) compared to placebo in seven healthy older 199 
adults who were regular caffeine consumers. Symptoms of PPH were not relevant to these 200 
two studies. [10, 20] 201 
In 20 regular caffeine drinking older adults with various co-morbidities, of whom four had 202 
symptoms suggestive of orthostatic or post-prandial hypotension, 100 mg of caffeine (given 203 
as coffee) resulted in a significant overall reduction in the sitting post-prandial fall in SBP 204 
compared to placebo (decaffeinated coffee).[11] No significant difference between placebo 205 
and caffeine phases was noted in DBP, or  in standing SBP between placebo and caffeine. 206 
Three participants were noted to have a fall in SBP consistent with PPH. Symptoms of PPH 207 
were alleviated by caffeine in two participants and not by placebo.[11] 208 
Lipsitz et al showed that caffeine (250mg) did not attenuate the decline in SBP, DBP or MAP 209 
associated with ingestion of a meal in nine patients with autonomic failure who experienced 210 
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symptomatic post-prandial hypotension.[22] Although this study included those with 211 
symptomatic PPH, there was no reporting of the effect of caffeine on symptoms. 212 
 213 
Acarbose 214 
In thirteen participants with autonomic failure and PPH, randomised to acarbose (100mg 215 
capsule) or placebo, given 20 minutes before a mixed meal, acarbose reduced the 216 
postprandial fall in supine SBP and DBP with no effect on HR and no adverse effects 217 
reported.[13] There was no specific reporting on the effects of treatment on symptoms. In 218 
another study, eight healthy older participants, randomised in a double-blind order to 219 
receive 100mg acarbose with an intraduodenal sucrose infusion (6kcal/min) or sucrose 220 
alone on two separate days, showed a similar attenuation in both the SBP and DBP, but this 221 
was accompanied by a rise in HR (p<0.05).[14] 222 
 223 
DL-DOPS 224 
The effect  of DL-DOPS (1000mg) given three hours pre-meal, on post-prandial BP was 225 
assessed in a cross-over study in eleven participants with autonomic failure.[15] The 226 
greatest BP fall occurred 30 minutes after the mixed meal and SBP (p=0.01) and DBP 227 
(p<0.01) falls were  significantly greater after placebo than with DL-DOPS.  There were no 228 
significant differences in HR between placebo or DL-DOPS and no effect on symptoms 229 
reported. 230 
 231 
Guar Gum 232 
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Three studies assessed the effect of guar gum against a placebo/control phase on post-233 
prandial BP in older adults after either a 50g glucose drink or intraduodenal 234 
glucose.[16,25,26] Jones and colleagues carried out a randomised cross-over trial in ten 235 
healthy adults and demonstrated that 9g of guar gum (compared to control) significantly 236 
reduced the fall in SBP (p=0.02), DBP (p<0.05) and MAP (p=0.05) 30 minutes post-prandially 237 
with no HR changes.[16] Russo et al, in a randomised cross-over, studied eleven participants 238 
with type 2 diabetes mellitus, showed that 9g guar gum significantly  (p<0.05) reduced the 239 
post-prandial fall in BP in response to a 50g oral glucose load.[25]  240 
The use of intraduodenal, rather than an oral, glucose load allows the observation of the 241 
changes in BP independent of any effects of the intervention on gastric emptying, the rate 242 
of gastric emptying influencing the fall in postprandial BP. [26] O’Donovan et al [27] 243 
demonstrated a significantly smaller fall in SBP, but not DBP, with 4g of guar gum after a 50g 244 
intraduodenal glucose infusion in eight healthy adults compared to the glucose only 245 
infusion[27]. 246 
 247 
Octreotide 248 
Three papers reporting the effect of subcutaneous octreotide on post-prandial BP did not 249 
include symptomatic PPH and symptoms of PPH were not considered.[17, 21, 28] However 250 
the data presented in two of these papers may report the same participant group.[17, 21]  251 
Jansen and colleagues [17, 21] included ten hypertensive and ten normotensive adults, who 252 
received either a single dose of subcutaneous octreotide (50µg) or placebo (saline) in a 253 
double blind randomised fashion together with a 75g glucose drink. Both the normotensive 254 
and hypertensive groups showed significant falls in MAP at 30 and 60 minutes with placebo 255 
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but showed no significant fall after octreotide.[21] A significant difference between placebo 256 
and octreotide was shown for the SBP (p=0.008), DBP (p<0.001) and MAP (p<0.001) in the 257 
hypertensive group and for diastolic (p=0.005) and MAP (p=0.007) in the normotensive 258 
group.[17] Alam et al [28] demonstrated in eighteen participants with autonomic failure and 259 
symptomatic orthostatic hypotension, that octreotide (1µg/kg body weight) compared to no 260 
treatment, reduced the post-prandial BP fall from 10 minutes up to 120 minutes, with 261 
octreotide reducing the fall in SBP (p<0.01) and DBP (p<0.05). There were no significant 262 
differences in HR and no adverse effects were reported. [28] 263 
 264 
Longer-term studies 265 
Caffeine 266 
Rakic et al enrolled 171 participants (98% regular caffeine drinkers), which included 267 
normotensives and treated or untreated hypertensives, who were randomised to a two 268 
week period of regular caffeine consumption (60mg five times daily) or no caffeine.[24] It 269 
was noted that the baseline post-prandial supine SBP falls were greater in those with 270 
untreated and treated hypertension compared to normotensives, with similar changes seen 271 
in standing SBP. Coffee significantly reduced the post-prandial fall in supine and standing 272 
SBP in regular coffee drinking normotensives and also in tea drinkers with treated 273 
hypertension. The effects on HR were not reported. Amongst those with untreated 274 
hypertension, the two week caffeine abstainers also had a significant reduction in the post-275 
prandial fall of supine SBP.  The effect of treatment on symptoms was not reported. 276 
Onrot et al considered the longer-term effects of caffeine, with five participants being 277 
administered caffeine as a 250mg capsule daily for seven days. Participants were then 278 
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randomised to receive placebo or caffeine as a single dose. Despite longer-term caffeine, 279 
the post-prandial BP still remained higher after caffeine (p<0.05) compared with the placebo 280 
following a standardised meal.[23]  281 
 282 
Results summary 283 
Table 3 shows a summary of the various drug effects on the post-prandial falls in BP. 284 
However it should be noted that the majority of studies were carried out in participants who 285 
did not specifically have either a diagnosis of post-prandial hypotension with a proven 286 
minimal fall in post-prandial BP, or whom had symptoms suggestive of post-prandial 287 
hypotension. [1]  288 
 289 
Discussion 290 
Despite PPH being associated with significant morbidity and mortality in older people, the 291 
evidence for the benefits of pharmacological intervention in reducing these BP falls is 292 
limited.  The studies included in this systematic review had great heterogeneity in terms of 293 
intervention drug type, dose, frequency and time of intervention relative to type and size of 294 
energy load.  Another important influencing factor on effect is the heterogeneity in the 295 
population studied e.g. healthy adults as oppose to those with hypertension and diabetes, 296 
those with autonomic dysfunction with only one study specifically investigated the effect on 297 
those with symptomatic post-prandial hypotension.  Thus caution is needed in the 298 
interpretation, and the use of, any therapeutic interventions based on the findings of this 299 
systematic review especially in older patients with symptomatic PPH. 300 
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This systematic review confirms that certain drug interventions may attenuate the post-301 
prandial fall in BP both when given as a once only intervention as well as following chronic 302 
use and is summarised in Table 3. However most notably the majority of studies do not 303 
specifically include participants with PPH symptoms or who had a confirmed diagnosis of 304 
post-prandial hypotension.[1] Some studies tried to overcome this by including those with a 305 
history of orthostatic hypotension (OH), but the underlying pathophysiology of OH and PPH 306 
probably differs, albeit both conditions can exist in the same patient. It is therefore difficult 307 
to conclusively state which drug is the best for post-prandial hypotension, particularly as 308 
adverse effects need to be considered, such as supine hypertension with DL-DOPs.[15]  309 
 310 
Post-prandial hypotension reflects the failure to maintain systemic blood pressure levels 311 
which fall as a result of a decrease in systemic resistance with blood being diverted into the 312 
splanchnic circulation.[1] Thus potential methods of decreasing PPH might focus on  313 
delaying the rate of food absorption from the gut or reducing local splanchnic bed 314 
vasodilation. However the drugs used to attenuate post-prandial falls in BP in this review 315 
have many differing mechanisms of action and the effects are likely to be variable, even 316 
more so between population groups.  317 
Caffeine, an adenosine blocker, has some supportive evidence of having a positive effect on 318 
reducing a post-prandial blood pressure fall in both infrequent and regular users, although 319 
only one small study looked specifically at patients with symptomatic post-prandial 320 
hypotension. [22] Furthermore when used in participants with autonomic failure caffeine 321 
reduced the post-prandial fall in the group mean SBP. [23] Caffeine increased MAP in the 322 
study by Lenders et al [20] when given an hour before the meal, however its maximal 323 
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potential effect on reducing PPH may have been negated by the time elapsed between 324 
treatment administration and likely maximum post-prandial BP fall.   The lack of effect on 325 
the erect SBP in the second study by Heseltine and colleagues [11] may have been due to 326 
the smaller dose of caffeine administered. Given that caffeine is readily available in the form 327 
of tea and coffee, its use in PPH could be simply part of a lifestyle change, though it would 328 
appear that a pre-prandial dose of at least 200 mg is needed. 329 
DL-DOPS by increasing noradrenaline [15] and acarbose by delaying gut glucose absorption 330 
[13, 14] were shown to attenuate the postprandial fall in BP. Furthermore acarbose was 331 
shown to attenuate PPH in those with severe autonomic failure [13]. One study [29] of 332 
acarbose in PPH patients did not randomise the order which participants the control and 333 
acarbose (50mg) and was therefore excluded from this systematic review, however it is 334 
worth noting it showed a statistically significant reduction in the post-meal fall in SBP (at 60 335 
minutes: 17.8±11.7mmHg to -4.2±13.1mmHg, p<0.001), DBP (-7.6±8.5mmHg to -336 
3.9±6.9mmHg, p<0.05) and MAP (-10.3±8.4mmHg to -3.3±8.1mmHg, p<0.05). Guar gum also 337 
by presumably delaying absorption attenuated the post-prandial BP declines, however in 338 
some instances the BP changes were small (<5mmHg) and of doubtful clinical significance. 339 
Octreotide subcutaneously attenuates the postprandial fall in BP amongst those with 340 
orthostatic hypotension and hypertension, as well as those who are classified as 341 
normotensive.  342 
The variability of timing of drug administration relative to the energy load (either a glucose 343 
drink, liquid meal or standardised mixed meal), as well as which BP parameters were 344 
recorded made it difficult to compare studies and include in a meta-analysis. Whilst some 345 
reported all BP parameters and HR changes others only reported MAP values, some only the 346 
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maximal post-prandial BP changes. For a “positive” treatment effect the majority of studies 347 
used the lack of a statistically significant fall in BP from baseline with the drug intervention, 348 
rather than a change that might be clinically significant. Furthermore the majority of studies 349 
(with the exception of two [10, 11]) did not explicitly measure BP on more than one 350 
occasion at each time point, although single measurements were carried out using validated 351 
methods.  Also of importance and not reported in the studies is the effect of treatment on 352 
symptoms in those with symptomatic PPH. 353 
The limitations of this systematic review include the fact that only studies reported in 354 
English were included and there were only a few studies available for each intervention. 355 
Furthermore we only included studies which were randomised and controlled in some way, 356 
but we did not require them to be blinded as this was difficult for the original investigators 357 
with some of the interventions. However this may be a potential source of bias from 358 
included studies. Furthermore the heterogeneity of study design and parameters assessed 359 
within the studies included in this systematic review prohibited meta-analysis. 360 
 361 
Overall the pharmacological agents included have been shown to have some effect on the 362 
attenuation of post-prandial falls in BP. However only two studies [13,22] examined the 363 
effect of a drug intervention (caffeine and acarbose) on post-prandial hypotension, where 364 
caffeine was found to be ineffective. Thus future studies should be directed at measuring 365 
the effect of these drug interventions on post-prandial hypotension compared to lifestyle 366 
changes including regular caffeine consumption in the form of tea or coffee.  Consideration 367 
should be given to other methods of reducing the post-prandial fall in BP such as altering 368 
meal composition in terms of energy load and carbohydrate type, paying particular 369 
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attention to their influence on PPH symptoms.  The effects of PPH and its treatment on 370 
other important vascular beds, e.g. cerebral blood flow control which may account for some 371 
of the symptoms, also justifies further research. The variable nature of the BP parameters 372 
measured in the current studies and the heterogeneity of the populations studied make it 373 
difficult to accurately project the results of this systematic review to our older patients with 374 
symptomatic post-prandial hypotension. The studies reviewed suggest that caffeine may be 375 
helpful in reducing post-prandial falls in BP, but may not be useful in those with PPH. The 376 
evidence also suggests that acarbose may similarly be of some benefit amongst those 377 
suffering from PPH.  378 
  379 
For the clinician managing older patients with symptomatic PPH, the most pragmatic 380 
approach appears to be give advice in: 1) avoiding large, simple carbohydrate meals; 2) to 381 
consume small frequent meals instead and 3) avoid alcohol (and other vasodilator agents) 382 
with meals. In some patients, having regular caffeinated beverages post-prandially may be 383 
of benefit in terms of PPH symptom reduction. 384 
 385 
Conclusion  386 
 387 
This systematic review highlights the limited data on the pharmacological treatment of PPH 388 
both in terms of reducing the postprandial BP fall and symptom improvement.  Future 389 
studies should investigate the effectiveness of drug treatment and lifestyle changes in 390 
symptomatic postprandial hypotension. In the meantime best pragmatic advice would be to 391 
Page 19 of 52 
 
Drug Treatment of Post-Prandial Falls in BP 
  14/11/13 
 
avoid large simple carbohydrate meals, alcohol and vasodilators and in some cases caffeine 392 
may also reduce PPH symptoms.  393 
 394 
395 
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Figure 1: Flow chart 
  
MEDLINE, CINAHL, EMBASE 
searches from 16th July 2013.  
3140 records found 
2759 records after de-duplication 
38 study abstracts examined 
2721 records excluded 
from title as not related 
to PPH 
22 study full papers obtained 
19 studies reviewed 
16 studies excluded from 
abstracts as not related to PPH 
3 excluded from paper (not drug 
intervention (1), not post-
prandial (1), only summary (1) 
5 studies excluded from final 
review as not randomised 
14 studies included in systematic 
review 
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Table 1: Study Characteristics 
 
Study  
Author (Year) 
[Reference] 
Drug/ 
Intervention 
Design/ 
duration 
Meal/Glucose Study Population Known 
PPH 
PPH defined 
in study 
Age 
(years) 
Number of 
participants 
Gender Groups 
Shorter-term studies(<24hours) 
Onrot et al. 
(1985) [23] 
Caffeine 
250mg 
capsule 
Study days 
randomised, 
consecutive 
participants,
not blind 
(<24hrs & 
>24hrs) 
Standard mixed 
meal (kcal not 
given) 
Autonomic failure 
(primary – 11, 
secondary -1) 
No N/A 63.6 (SD ± 
5.9) 
12 6M:6F Meal(12)/ 
Caffeine(12)/ 
Meal & 
Caffeine (6) 
Lenders et al. 
(1988) [20] 
Caffeine 
250mg 
capsule 
Randomised, 
double blind, 
controlled, 
cross-over 
(<24hrs) 
Standard mixed 
meal (405kcal) 
Healthy No N/A 75.4 (SD ± 
6.6) 
15 8M:7F Placebo(15)/ 
Caffeine(15) 
Heseltine et 
al. (1991) [10] 
Caffeine 
200mg coffee 
Randomised, 
double blind, 
controlled, 
cross-over 
(<24hrs) 
Standard mixed 
meal (585kcal) 
Healthy No N/A 67.4 (range 
64-72) 
7 2M:5F Placebo(7)/ 
Caffeine(7) 
Heseltine et 
al. (1991) [11] 
Caffeine 
100mg coffee 
Randomised, 
double blind, 
controlled, 
cross-over 
(<24hrs) 
Glucose drink 
(400kcal) 
Post-acute admission 
(CVD, IHD, CCF, 
PVD, DM, COPD, 
PD) 
No N/A 84 (SD ± 5) 20 10M:10F Decaffeinated 
(20)/ 
Caffeine(20) 
Lipsitz et al. 
(1994) [22] 
Caffeine 
250mg 
capsule 
Randomised, 
double blind, 
controlled, 
cross-over 
(<24hrs) 
Liquid mixed 
meal (1674kJ) 
Pure autonomic 
failure, Shy-Drager, 
PD, unknown 
Yes ≥20mmHg fall 
supine/seated 
SBP ≤60mins 
of meal 
79 (SD ± 9) 9 2M:7F Placebo (9)/ 
Caffeine (9) 
Shibao et al. 
(2007) [13] 
Acarbose 
100mg 
Randomised, 
single & 
double blind, 
controlled, 
standard mixed 
meal (414kcal) 
Pure autonomic 
failure (12), PD (1) 
[secondary cause 
excluded] 
Yes ≥20mmHg fall 
in SBP 
≤120mins 
65 (SD ± 
2.64) 
13 5M:8F Placebo (13)/ 
Acarbose (13) 
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cross-over 
(<24hrs) 
Gentilcore et 
al. (2011) [14] 
Acarbose 
100mg 
Randomised, 
double blind, 
controlled, 
cross-over 
(<24hrs) 
Intraduodenal 
sucrose (100g in 
300ml 0.9% 
NaCl, 5ml/min, 
6kcal/min) 
Healthy No N/A Median 70 
(range 66-
77) 
8 4M:4F No acarbose/ 
Acarbose 
Freeman et al. 
(1996) [15] 
DL-DOPS 
1000mg 
Randomised, 
double blind, 
controlled, 
cross-over 
(<24hrs) 
standard mixed 
meal (400kcal) 
All Orthostatic 
hypotension 
(undefined by BP); 
mix of MSA, PD, 
PAF 
No N/A 54 (SD ± 13) 11 7M:4F Placebo (11)/ 
DL-DOPS 
(11) 
Jones et al. 
(2001) [16] 
Guar gum 9g Randomised, 
not blind, 
controlled, 
cross-over 
(<24hrs) 
50g glucose 
drink 
Healthy No 30 min 
sustained fall 
SBP 
≥20mmHg 
median 70 
(range 67-
78) 
10 5M:5F Guar gum/ No 
guar gum 
Russo et al. 
(2003) [25] 
Guar gum 9g Randomised, 
not blind, 
controlled, 
cross-over 
(<24hrs) 
50g glucose 
drink 
Type 2 DM No 30 min 
sustained fall 
SBP 
≥20mmHg 
median 61 
(range 57-
69) 
11 8M:3F Guar gum/ No 
guar gum 
O'Donovan et 
al. (2005) [27] 
Guar gum 4g Randomised, 
double blind, 
controlled, 
cross-over 
(<24hrs) 
Intraduodenal 
glucose infusion 
(50g in 300ml 
water, 5ml/min, 
3kcal/min) 
Healthy No N/A 70.3 (SD ± 
3.4) 
8 4M:4F Guar gum/ No 
guar gum 
Jansen et al. 
(1988) [21] 
Octreotide 
50µg SC 
Randomised, 
double blind, 
controlled, 
cross-over 
(<24hrs) 
75g glucose 
drink 
Normotensive, HTN No No 74 (SD ± 4) 20 unknown Placebo/ 
octreotide 
Jansen et al. 
(1989) [17] 
Octreotide 
50µg SC 
Randomised, 
double blind, 
controlled, 
cross-over 
(<24hrs) 
75g glucose 
drink 
Normotensive, HTN No No 74 (SD ± 4) 20 7M:13F Placebo/ 
octreotide 
Alam et al. 
(1995) [28] 
Octreotide 
1µg/kg SC bd 
Randomised, 
not blind, 
Meal 
(unspecified) 
Symptomatic OH 
(fall ≥30mmHg 
No No range 44-73 18 11M:7F Octreotide/ No 
octreotide 
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(8am,6pm) controlled, 
cross-over 
(<24hrs) 
SBP); PAF, Shy-
Drager. [Secondary 
causes excluded] 
 
Longer-term studies (>24 hours) 
Rakic et al. 
(1996) [24] 
Caffeine 60mg 
5 times/day as 
tea/ coffee 
Randomised, 
not blind, 
controlled, 
cross-over 
(>24hrs) 
High 
carbohydrate 
meal 
(unspecified) 
Normotensive 
(62)/treated HTN 
(46)/untreated HTN 
(63) 
No N/A 75.2 (SD ± 
0.7) 
171 41M:127F Decaffeinated/ 
Caffeine 
Onrot et al. 
(1985) [23] 
Caffeine 
250mg 
capsule 
Study days 
randomised, 
consecutive 
participants,
not blind 
(<24hrs & 
>24hrs) 
Standard mixed 
meal (kcal not 
given) 
Autonomic failure 
(primary – 11, 
secondary -1) 
No N/A 63.6 (SD ± 
5.9) 
12 6M:6F Meal(12)/ 
Caffeine(12)/ 
Meal & 
Caffeine (6) 
 
Key: DM=diabetes mellitus; HTN=hypertension; OH=orthostatic hypotension; PAF=pure autonomic failure; MSA=multi-system atrophy; PD=Parkinson 
disease; CVD=cerebrovascular disease; PVD=peripheral vascular disease; IHD=ischemic heart disease; CCF=congestive cardiac failure; COPD=chronic 
obstructive pulmonary disease  
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Table 2: Assessment of Risk of Bias 
Study  
(Author, Year, 
Reference) 
Adequate sequence 
generation 
Allocation concealment Incomplete outcome 
data addressed 
Free of 
selective 
reporting 
Free of other bias 
Shorter-term studies (<24 hours) 
Onrot et al. (1985) 
[23] 
Study days randomised 
(unclear method), 
consecutive patients 
Not blinded, controlled 
Unclear concealment 
Yes Yes Yes 
Lenders et al. 
(1988) [20] 
Study days randomised 
(unclear method), cross-
over 
Double blind, controlled 
Unclear concealment 
Yes Yes Yes 
Heseltine et al. 
(1991) [10] 
Randomised (unclear 
method), cross-over 
Double blind, controlled 
Unclear concealment 
Yes Yes Yes 
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Heseltine et al. 
(1991) [11] 
Randomised (unclear 
method), cross-over 
Double blind, controlled 
Unclear concealment 
Yes Yes Yes 
Lipsitz et al. 
(1994) [22] 
Randomised (unclear 
method), cross-over 
Double blind, controlled 
Unclear concealment 
Yes Yes Yes 
Shibao et al. 
(2007) [13] 
Randomised (unclear 
method used, but different 
department), cross-over 
Single & Double blind, 
controlled 
Identical color capsules 
used to maintain 
concealment 
Yes Yes Yes 
Gentilcore et al. 
(2011) [14] 
Randomised (unclear 
method), cross-over 
Double blind, controlled 
Unclear concealment 
 
Yes Yes Yes 
Freeman et al. Randomised (unclear Double blind, controlled Yes Yes Yes 
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(1996) [15] method used, but different 
department), cross-over 
Identical color capsules 
used to maintain 
concealment 
Jones et al. (2001) 
[16] 
Randomised (unclear 
method), cross-over 
Not blinded (due to 
viscosity of drink), 
controlled 
Yes Yes Yes 
Russo et al. (2003) 
[25] 
Randomised (unclear 
method), cross-over 
Not blinded (due to 
viscosity of drink), 
controlled 
Yes Yes Yes 
O’Donovan et al. 
(2005) [27] 
Randomised (unclear 
method), cross-over 
Single blind, controlled 
Unclear concealment 
Yes Yes Yes 
Jansen et al. (1988) 
[21] 
Randomised (unclear 
method), cross-over 
Double blind, controlled 
Placebo injection used to 
maintain concealment 
Yes Yes Unclear. It appears the same 
study data was published in 
two journals. 
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Jansen et al. (1989) 
[17] 
Randomised (unclear 
method), cross-over 
Double blind, controlled 
Placebo injection used to 
maintain concealment 
Yes Yes Unclear. It appears the same 
study data was published in 
two journals. 
Alam et al. (1995) 
[28] 
Randomised (unclear 
method), cross-over 
Not blinded, controlled 
Unclear concealment 
Yes Yes Yes 
Longer term studies(>24 hours) 
Onrot et al. (1985) 
[23] 
Study days randomised 
(unclear method), 
consecutive patients 
Not blinded, controlled 
Unclear concealment 
Yes Yes Yes 
Rakic et al. (1996) 
[24] 
Randomised (unclear 
method), cross-over 
Not blinded, controlled 
Unclear concealment  
Yes Yes Yes 
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Table 3: Overall Study Conclusion for Alleviating Post-Prandial Falls in BP or PPH 
Study (Author, Year, 
Reference) 
Participant 
Group 
Drug Approximate 
Maximal Mean 
Change in BP 
Compared to Baseline 
(mmHg) * 
Maximal BP 
change at 
time from 
baseline 
(minutes) 
Difference 
between 
Control and 
Intervention 
Arm in 
Approximate 
Maximal 
Mean Change 
in BP 
(mmHg) 
Adverse 
events 
Shorter-term studies (<24 hours) 
Onrot et al. (1985) 
[23] 
Autonomic 
Failure 
Caffeine (250mg 
capsule) 
SBP: -3 
DBP: -6 
60 SBP: 20 
DBP: 8 
None reported 
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Control SBP: -23 
DBP: -14 
60 
Lenders et al. (1988) 
[20] 
Healthy 
participants 
Caffeine (250mg 
capsule) 
MAP: 0% (maximal 
increase of 12.5%) 
30-60 MAP: 6.1% None reported 
Control MAP: -6.1% 30-60 
Heseltine et al. 
(JAGS, 1991) [10] 
Healthy 
participants 
Caffeine (200mg 
coffee) 
SBP: 12 90 SBP: 29 None reported 
Control  SBP: -17 60 
Heseltine et al. 
(PMJ, 1991) [11] 
Multiple 
comorbidities (4 
of 20 had 
symptoms 
suggestive of 
PPH or OH) 
Caffeine (100mg 
coffee) 
Sitting SBP: 2 60 SBP: 10 Symptomatic 
postural 
hypotension 
with placebo 
Control Sitting SBP: -8 60 
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Lipsitz et al. (1994) 
[22] 
Autonomic 
Failure 
Caffeine (250mg 
capsule) 
MAP: -31 30 MAP: 12 None reported 
Control MAP: -19 30 
Rakic et al. (1996) 
[24] 
Normotensive/Hy
pertension/Untrea
ted Hypertension 
Caffeine (60mg 
tea/coffee) 
Standing SBP: -8 
(UHTN), -9 (HTN), -3 
(NTN) 
60 SBP: 2 
(UHTN), 3 
(HTN), 5 
(NTN) 
None reported 
Control Standing SBP: -10 
(UHTN), -12 (HTN), -8 
(NTN) 
60 
Shibao et al. (2007) 
[13] 
Autonomic failure Acarbose SBP: -17 60 SBP: 23 None reported 
Control SBP: -40 60 
Gentilcore et al. 
(2011) [14] 
Healthy Acarbose SBP: -1 
DBP: -3 
15-30 
15-30 
SBP: 7 
DBP: 6 
Flatulence, 
loose stools 
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Control SBP: -8 
DBP: -9 
15-30 
15-30 
Freeman et al. 
(1996) [15] 
Autonomic failure DL-DOPS MBP: -13 
SBP: -34 
DBP: -16 
30 
30 
30 
MBP: 17 
SBP: 8 
DBP: 6 
Pattern of 
supine 
hypertension 
(not 
statistically 
significant) 
Control MBP: -30 
SBP: -42 
DBP: -22 
30 
30 
30 
Jones et al. (2001) 
[16] 
Healthy  Guar gum SBP: -4 
DBP: -6 
MBP: -4 
15-30 
15-30 
15-30 
SBP:3 
DBP: 1 
MBP: 4 
“well 
tolerated”, 
mild dizziness 
and faintness 
with glucose Control  SBP: -7 15-30 
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DBP: -7 
MBP: -8 
15-30 
15-30 
Russo et al. (2003) 
[25] 
Type 2 diabetes 
mellitus 
Guar gum SBP: -2.5 
DBP: -2.9 
MAP: -6.8 
30 
30 
30 
SBP: 2.4 
DBP: 2.6 
MAP: 3.4 
None reported 
“well 
tolerated” 
Control SBP: -4.9 
DBP: -5.5 
MAP: -10.2 
30 
30 
30 
O’Donovan et al. 
(2005) [27] 
Healthy Guar gum SBP: -2.5 
DBP: -4 
15-30 SBP: 8.5 
DBP: 1 
None reported 
“well 
tolerated” 
Control SBP: -11 
DBP: -5 
15-30 
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Jansen et al. (1988) 
[21] 
Hypertension and 
Normotensive 
Octreotide MAP: 0 (NTN), -2 
(HTN) 
60 MAP: 7 
(NTN), 12 
(HTN) 
None reported 
Control MAP: -7 (NTN), -14 
(HTN) 
60 
Jansen et al. (1989) 
[17] 
Hypertension and 
Normtensive 
Octreotide SBP: 1 (NTN), -1 
(HTN) 
DBP: 0 (NTN), 0 
(HTN) 
60 
60 
SBP: 6 (NTN), 
11 (HTN) 
DBP: 9 
(NTN), 15 
(HTN) 
injections 
uncomfortable, 
“some” 
increased 
defaecation, 
slight 
abdominal 
pain 
Control SBP: -5 (NTN), -12 
(HTN) 
DBP: -9 (NTN), -15 
(HTN) 
60 
 
60 
Alam et al. (1995) Autonomic failure Octreotide SBP: 0 10 SBP: 3 None reported 
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[28] DBP: -2 10 DBP: 3 
Control SBP: -3 
DBP: -5 
10 
10 
Longer-term studies (>24 hours) 
Onrot et al. (1985) 
[23] 
Autonomic 
Failure 
Caffeine (250mg 
capsule) 
SBP: -3 
DBP: -6 
60 SBP: 20 
DBP: 8 
None reported 
Control SBP: -23 
DBP: -14 
60 
Rakic et al. (1996) 
[24] 
Normotensive/Hy
pertension/Untrea
ted Hypertension 
Caffeine (60mg 
tea/coffee) 
Standing SBP: -8 
(UHTN), -9 (HTN), -3 
(NTN) 
60 SBP: 2 
(UHTN), 3 
(HTN), 5 
(NTN) 
None reported 
Control Standing SBP: -10 
(UHTN), -12 (HTN), -8 
60 
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(NTN) 
Key: * Note that many values are estimated from graphs depicted by original authors. UHTN= Untreated Hypertension, HTN = Hypertension, NTN = 
Normotensive. A negative (-) sign indicates a fall in BP.
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Supplementary Information 
Table A: Critical Appraisal of Studies using CASP 
St
ud
y 
Fo
cu
se
d 
is
su
e 
Ra
nd
om
is
ed
 
Pa
rt
ic
ip
an
ts
 a
cc
ou
nt
ed
 
fo
r 
“B
lin
d”
 to
 tr
ea
tm
en
t 
G
ro
up
s s
im
ila
r 
G
ro
up
s t
re
at
ed
 
eq
ua
lly
 
Tr
ea
tm
en
t e
ff
ec
t &
 
Pr
ec
is
io
n 
of
 e
ff
ec
t 
(m
m
Hg
) 
Ap
pl
ic
at
io
n 
of
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su
lts
 
Im
po
rt
an
t o
ut
co
m
es
 
co
ns
id
er
ed
 
Be
ne
fit
s o
ut
w
ei
gh
 
ha
rm
s/
co
st
s 
Onrot et al. 
(1985) [23] 
Yes Study 
days 
only 
Yes No Yes Yes SBP: 132±34 (baseline) 
to 129±31 (caffeine) 
DBP: 75±16 (baseline) to 
69±13 (caffeine) 
SBP from 131±34 to 
108±21 (control) 
DBP from 76±16 to 
Autonomic 
failure, not 
proven PPH 
No measure of 
symptom 
improvement 
Yes 
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62±14 (control) 
Lenders et 
al. (1988) 
[20] 
Yes Yes Yes Yes Yes Yes MAP: 12.5% increase 
(caffeine), no change 
(control) 
Healthy No measure of 
symptom 
improvement 
Yes 
Heseltine 
et al. 
(JAGS, 
1991) [10] 
Yes Yes Yes Yes Yes Yes SBP: 12, 95% CI: 4 to 20 
(caffeine) vs -17, 95% CI: 
-5 to -20 (control) 
Healthy No measure of 
symptom 
improvement 
Yes 
Heseltine 
et al. (PMJ, 
1991) [11] 
Yes Yes Yes Yes Yes Yes SBP: 2, 95% CI: 0 to 4 
(caffeine) vs -8, 95% CI: -
10 to -6 (control)  
Hospital 
patients 
No measure of 
symptom 
improvement 
Yes 
Lipsitz et 
al. (1994) 
[22] 
Yes Yes Yes Yes Yes Yes MAP: -31±SEM 7 
(caffeine) vs -19 ±SEM 6 
(control) [between group 
PPH No measure of 
symptom 
improvement 
Yes 
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difference not 
significant] 
Rakic et al. 
(1996) [24] 
Yes Yes Yes Yes Yes Yes Figures given, estimated 
values. 
NTN: -7, UHTN: 15, HTN: 
-15 (caffeine, supine) 
NTN: -11, UHTN: -17.5, 
HTN: -14 (control, 
supine) 
NTN, HTN, 
Untreated 
HTN 
No measure of 
symptom 
improvement 
Yes 
Shibao et 
al. (2007) 
[13] 
Yes Yes Yes Yes Yes Yes increased SBP: 17, 95% 
CI: 7 to 28 (acarbose) 
increased 
DBP: 9, 95% CI: 5 to 14 
PPH No measure of 
symptom 
improvement 
Yes 
Page 47 of 52 
 
Drug Treatment of Post-Prandial Falls in BP 
  14/11/13 
 
(acarbose) 
Gentilcore 
et al. 
(2011) [14] 
Yes Yes Yes Yes Yes Yes SBP: no fall (acarbose) vs 
-11.2±2 (control) 
DBP: -8.1±1.5 (acarbose) 
vs -10.9±0.9 (control) 
Healthy No measure of 
symptom 
improvement 
Yes 
Freeman et 
al. (1996) 
[15] 
Yes Yes Yes Yes Yes Yes SBP: 147.8± SD 12.9 (DL-
DOPS)  vs 127± SD 11.4 
(control)  
DBP: 81.7± SD 18.6 (DL-
DOPS) vs 69.5± SD 12.6  
(control)  
OH No measure of 
symptom 
improvement 
Unclear 
Jones et al. 
(2001) [16] 
Yes Yes Yes No Yes Yes Figures used, estimated 
values. 
Healthy No measure of 
symptom 
Yes 
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SBP: 119±SEM 4 
(baseline) to 115±5 
(guar) vs 117±5 to 110±5 
(control) 
DBP: 63.5±3 (baseline) 
to 61.5±4 (guar) vs 
64.5±3 to 56.6±4 
(control) 
MBP: -4 (guar) vs -8 
(control) 
 
improvement 
Russo et al. 
(2003) [25] 
Yes Yes Yes No Yes Yes SBP: 145.1±4.8 (baseline) 
142.6±4.5 (glucose) [guar 
gum] vs 143.9±4.7 
Type 2 DM No measure of 
symptom 
improvement 
For SBP 
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(baseline) to 139.0±4.2 
(glucose) [control] 
 
O’Donovan 
et al. 
(2005) [27] 
Yes Yes Yes Yes Yes Yes Figures used, estimated 
post-prandial values: 
SBP: -2.5±2.5 (guar) vs -
11±2.5  (control)  
DBP: -5±3 (guar) vs -4±2 
(control) 
Healthy No measure of 
symptom 
improvement 
For SBP 
Jansen et 
al. (1988) 
[21] 
Yes Yes Yes Yes Yes Yes NTN: MAP 94±2 
(baseline) to 87±2 
(control) vs 
95±2 (baseline) to 95±2 
NTN, HTN No measure of 
symptom 
improvement 
Unclear 
as no 
comme
nt on 
adverse 
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(octreotide) 
HTN: MAP 123±3 
(baseline) to 109±3 
(control) vs 
122±3 (baseline) to 
120±3 (octreotide) 
events 
Jansen et 
al. (1989) 
[17] 
Yes Yes Yes Yes Yes Yes Figures presented. HTN: 
control vs octreotide SBP 
p=0.008, DBP p<0.001, 
MAP p<0.001 
NTN: control vs 
octreotide DBP p=0.005, 
MAP p=0.007 
NTN, HTN No measure of 
symptom 
improvement 
Unclear 
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Alam et al. 
(1995) [28] 
Yes Yes Yes No Yes Yes Post-prandial SBP: 122±5 
(octreotide) vs 107±3 
(control) 
DBP: 75±4 (octreotide) 
vs 65±2 (control) 
OH No measure of 
symptom 
improvement 
No 
comme
nt on 
adverse 
events 
Key: NTN = normotension, UHTN = untreated hypertension, HTN = hypertension, SBP = systolic BP, DBP = diastolic BP, MAP = mean arterial pressure, PPH = 
post-prandial hypotension, OH = orthostatic hypotension, DM = diabetes mellitus 
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